Key result
Procedural sedation and analgesia prevent postprocedural ICU admissions and complications in fragile cardiac patients.
Why the study?
Interest in percutaneous high-tech cardiac procedures has increased alongside their safety and efficacy, creating a need to discuss the role of procedural sedation and analgesia in fragile patients across common contemporary procedures.
What is the role of procedural sedation and analgesia in fragile patients undergoing percutaneous high-tech cardiac procedures?
What is the role of procedural sedation and analgesia in fragile patients undergoing percutaneous high-tech cardiac procedures?
Procedural sedation and analgesia is a viable and increasingly utilized strategy for fragile patients undergoing complex percutaneous cardiac procedures to minimize ICU stays and complications.
Answers are grounded in this paper and cite their sources.
May support reduced ICU needs via sedation in fragile patients; leaves open need for prospective trials.
The interest in percutaneous high-tech cardiac procedures has increased in recent years together with its safety and efficacy. In fragile patients, procedural sedation and analgesia are used to perform most of the procedures. General anesthesia remains the technique of choice during the team learning curve and might be required in selected patients or in emergent situations. Despite the high costs of percutaneous high-tech cardiac procedures, the decrease in length of hospital stays, rate of intensive care admission and complications, balance the increase in devices costs. In fragile patients who undergo percutaneous high tech cardiac procedures, the primary role of the anesthesiologist is to prevent the need for postprocedural intensive care unit and complications rate. Starting from the experience of a large university third level hospital we identified the eight most commonly performed contemporary percutaneous high tech cardiac procedures (ventricular tachycardia and atrial fibrillation ablation, protected percutaneous coronary intervention, transcatheter aortic valve implantation, MitraClip® (Abbott Laboratories; Abbott Park, IL, USA), percutaneous patent foramen ovale closure, left atrial appendage closure, and dysfunctional lead extraction), discuss the role of procedural sedation and analgesia in this setting, and explore future perspectives.
No takes yet. Share an insight, caveat, or question.
Zangrillo et al. (2021) conducted a review in Fragile patients undergoing percutaneous high-tech cardiac procedures. Procedural sedation and analgesia vs. General anesthesia was evaluated. Procedural sedation and analgesia play a primary role in preventing the need for postprocedural intensive care unit admission and complications in fragile patients undergoing high-tech cardiac procedures.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: